Aerie Pharmaceuticals Inc 's

• AERI's Stock Performance relative to its Competitors

Adverum Biotechnologies Inc Share Performance +4.81% Over The Past 5 Days

Adverum Biotechnologies Inc Profile Adverum Biotechnologies Inc's business model is focused on developing gene therapies using its proprietary platform to deliver therapeutics for eye diseases. More about Adverum Biotechnologies Inc 's Market Share

Protara Therapeutics Inc Share Performance -13.87% This Quarter

Protara Therapeutics Inc Profile Protara Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapies to address significant unmet medical needs. Their business model revolves around identifying and advancing potential drug candidates that target specific diseases or conditions, conducting extensive research and development to ensure safety and efficacy, and ultimately seeking regulatory approvals and entering the market to make these therapies accessible to patients worldwide. Protara leverages collaborations and partnerships within the healthcare industry to support their research efforts and drive business growth. More about Protara Therapeutics Inc's Market Share

Ocular Therapeutix Inc Share Performance +1.32% Over The Past 5 Days

Ocular Therapeutix Inc Profile Ocular Therapeutix Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for diseases and conditions of the eye. They utilize their proprietary hydrogel technology to design and manufacture sustained-release treatments that can be administered during routine eye exams and eliminate the need for patient compliance with eye drops. More about Ocular Therapeutix Inc 's Market Share

Oculis Holding Ag Share Performance -24.20% 30 Days

Oculis Holding Ag Profile Oculis Holding Ag is a pharmaceutical company that specializes in developing and commercializing innovative ophthalmic treatments. Their business model revolves around conducting in-depth research and development to formulate eye medications that target various ocular diseases. They then seek regulatory approvals and form strategic partnerships to manufacture and distribute their products globally, aiming to improve eye health and provide effective treatment options for patients. More about Oculis Holding Ag's Market Share

Ocugen Inc Share Performance +0.20% Over The Past 5 Days

Ocugen Inc Profile Ocugen Inc's business model is focused on the development and commercialization of innovative gene therapies to treat rare and underserved ocular diseases, with a particular emphasis on underserved patient populations. They aim to leverage their expertise in gene therapy and partnerships to advance novel treatments and bring them to market, ultimately improving the lives of patients in need. More about Ocugen Inc 's Market Share

Sources: Aerie Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Friday, September 18, 2026 1:14 PM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Aerie Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.